Compare AARD & CTAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AARD | CTAA |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.8M | 166.0M |
| IPO Year | 2025 | 2026 |
| Metric | AARD | CTAA |
|---|---|---|
| Price | $6.07 | $9.95 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $15.29 | N/A |
| AVG Volume (30 Days) | ★ 116.4K | 1.9K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $9.88 |
| 52 Week High | $17.94 | $10.00 |
| Indicator | AARD | CTAA |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 57.88 |
| Support Level | $5.12 | $9.91 |
| Resistance Level | $6.43 | $10.00 |
| Average True Range (ATR) | 0.83 | 0.01 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 36.65 | 90.00 |
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
ClearThink 1 Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.